AN2 Therapeutics, Inc. (ANTX) Misses Q1 EPS by 6c

AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported Q1 EPS of ($0.29), $0.06 worse than the analyst estimate of ($0.23).

For earnings history and earnings-related data on AN2 Therapeutics, Inc. (ANTX) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Boeing and Bell Boeing receive defense contracts totaling $56.4M